This site is intended for healthcare professionals
Drug news

Lower rates of hypoglycaemia with Ryzodeg compared to insulin aspart-Novo Nordisk

Read time: 1 mins
Last updated:4th Dec 2013
Published:4th Dec 2013
Source: Pharmawand

Data presented at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with Type 2 Diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance period (defined as week 16 onwards) with Ryzodeg compared to biphasic insulin aspart 30, both administered twice-daily. Ryzodeg is the first combination of two distinct insulin analogues, Tresiba (insulin degludec), the once-daily basal insulin with an ultra-long duration of action, and the well-established mealtime insulin NovoRapid (insulin aspart), in the ratio of 70% and 30%, in one pen for people with Type 2 Diabetes.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.